BACKGROUND: Little is known about the ocular penetration of echinocandin antifungals. We studied the ocular distribution of systemically administered caspofungin in a rabbit uveitis model. METHODS: Caspofungin (1 mg/kg per day) was given intravenously to rabbits as a single dose or as repeated daily doses on 7 days starting 24 h after induction of unilateral uveitis by intravitreal endotoxin injection. Caspofungin concentrations were determined by high-performance liquid chromatography in the cornea, aqueous humor, vitreous humor, and serum 4, 8, 16, and 24 h after administration of a single dose and 24 h after the last of seven doses. RESULTS: The mean caspofungin concentration in the aqueous of the inflamed eye 4 and 8 h after single-dose administration was 1.30 +/- 0.39 microg/ml and 1.12 +/- 0.34 microg/ml, respectively. Drug concentrations decreased to 0.24 +/- 0.09 microg/ml at 16 h and 0.26 +/- 0.14 microg/ml at 24 h. In the vitreous of inflamed eyes drug levels were undetectable at all time points. No drug was found in the aqueous of inflamed eyes 24 h after the last of seven repeated doses, and the vitreous only contained trace amounts. In the corneas of inflamed eyes concentrations reached 1.64 +/- 0.48 microg/g at 4 h, peaked at 2.16 +/- 1.14 microg/g at 8 h, and declined to 1.87 +/- 0.52 microg/g and 1.49 +/- 0.48 microg/g at 16 and 24 h, respectively. After repeated dosing, corneal concentrations of caspofungin were 0.8 and 1.0 microg/g and below the limit of detection in two of four animals. In non-inflamed eyes no drug was detectable in the aqueous and vitreous humor, and the corneas at any time point. CONCLUSIONS: In our model, caspofungin reached therapeutically relevant levels in the aqueous and cornea but not in the vitreous humor of inflamed eyes. Intraocular drug deposition was critically dependent on a disrupted blood-eye barrier. These findings suggest a limited role for caspofungin in the treatment of fungal endophthalmitis.
BACKGROUND: Little is known about the ocular penetration of echinocandin antifungals. We studied the ocular distribution of systemically administered caspofungin in a rabbit uveitis model. METHODS: Caspofungin (1 mg/kg per day) was given intravenously to rabbits as a single dose or as repeated daily doses on 7 days starting 24 h after induction of unilateral uveitis by intravitreal endotoxin injection. Caspofungin concentrations were determined by high-performance liquid chromatography in the cornea, aqueous humor, vitreous humor, and serum 4, 8, 16, and 24 h after administration of a single dose and 24 h after the last of seven doses. RESULTS: The mean caspofungin concentration in the aqueous of the inflamed eye 4 and 8 h after single-dose administration was 1.30 +/- 0.39 microg/ml and 1.12 +/- 0.34 microg/ml, respectively. Drug concentrations decreased to 0.24 +/- 0.09 microg/ml at 16 h and 0.26 +/- 0.14 microg/ml at 24 h. In the vitreous of inflamed eyes drug levels were undetectable at all time points. No drug was found in the aqueous of inflamed eyes 24 h after the last of seven repeated doses, and the vitreous only contained trace amounts. In the corneas of inflamed eyes concentrations reached 1.64 +/- 0.48 microg/g at 4 h, peaked at 2.16 +/- 1.14 microg/g at 8 h, and declined to 1.87 +/- 0.52 microg/g and 1.49 +/- 0.48 microg/g at 16 and 24 h, respectively. After repeated dosing, corneal concentrations of caspofungin were 0.8 and 1.0 microg/g and below the limit of detection in two of four animals. In non-inflamed eyes no drug was detectable in the aqueous and vitreous humor, and the corneas at any time point. CONCLUSIONS: In our model, caspofungin reached therapeutically relevant levels in the aqueous and cornea but not in the vitreous humor of inflamed eyes. Intraocular drug deposition was critically dependent on a disrupted blood-eye barrier. These findings suggest a limited role for caspofungin in the treatment of fungal endophthalmitis.
Authors: Marlene L Durand; Ivana K Kim; Donald J D'Amico; John I Loewenstein; Ellis H Tobin; Shalom J Kieval; Stephen S Martin; Dimitri T Azar; Frederick S Miller; Brandon J Lujan; Joan W Miller Journal: Am J Ophthalmol Date: 2005-09 Impact factor: 5.258
Authors: Eduardo G Arathoon; Eduardo Gotuzzo; L Miguel Noriega; Rayanne S Berman; Mark J DiNubile; Carole A Sable Journal: Antimicrob Agents Chemother Date: 2002-02 Impact factor: 5.191
Authors: Jorge Mora-Duarte; Robert Betts; Coleman Rotstein; Arnaldo Lopes Colombo; Luis Thompson-Moya; Juanita Smietana; Robert Lupinacci; Carole Sable; Nicholas Kartsonis; John Perfect Journal: N Engl J Med Date: 2002-12-19 Impact factor: 91.245
Authors: Chin Fen Neoh; Hui He; Jian Li; Robert O Fullinfaw; Lok Leung; Anant Misra; Rasik B Vajpayee; Geoffrey E Davies; Kay Stewart; David C M Kong Journal: Antimicrob Agents Chemother Date: 2010-07-26 Impact factor: 5.191
Authors: Deb K Mojumder; Francis A Concepcion; Shil K Patel; Andrew J Barkmeier; Petros E Carvounis; John H Wilson; Eric R Holz; Theodore G Wensel Journal: Invest Ophthalmol Vis Sci Date: 2010-05-26 Impact factor: 4.799
Authors: Chin Fen Neoh; Jovan Jacob; Lok Leung; Jian Li; Angela Stathopoulos; Kay Stewart; David C M Kong Journal: Antimicrob Agents Chemother Date: 2012-04-02 Impact factor: 5.191
Authors: Chin Fen Neoh; Lok Leung; Anant Misra; Rasik B Vajpayee; Geoffrey E Davies; Robert O Fullinfaw; Kay Stewart; David C M Kong Journal: Antimicrob Agents Chemother Date: 2011-01-24 Impact factor: 5.191
Authors: Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel Journal: Clin Infect Dis Date: 2015-12-16 Impact factor: 9.079
Authors: S Blazaki; C Tsika; M Tzatzarakis; E Naoumidi; A Tsatsakis; C Tsatsanis; Miltiadis K Tsilimbaris Journal: Graefes Arch Clin Exp Ophthalmol Date: 2017-09-29 Impact factor: 3.117